ADSCC Achieves Milestone With Development Of Virus-Free Clinical-Grade Induced Pluripotent Stem Cells

The Abu Dhabi Stem Cells Center (ADSCC) has achieved a significant milestone in cell therapy and regenerative medicine. They have developed clinical-grade induced pluripotent stem cells (iPSCs) adhering to Good Manufacturing Practice protocols, meeting international standards for clinical use. This breakthrough positions ADSCC as a leader in stem cell research within the Middle East, setting a global standard for innovation and safety in precision medicine.

iPSCs are derived by reprogramming adult cells, like skin or blood cells, back to an embryonic-like state. These cells can transform into various types of human body cells. This allows for personalised therapies using a patient's own cells, reducing the risk of immune rejection and the need for immunosuppressive drugs.

iPSCs represent a major advancement in biomedical science, offering potential treatments for neurodegenerative diseases like Parkinson’s, Alzheimer’s, and multiple sclerosis, as well as conditions such as diabetes. ADSCC is actively conducting research projects exploring iPSCs' therapeutic applications for these diseases.

Professor Yendry Ventura, CEO of ADSCC and Principal Investigator in the Capital Organ Regeneration (CORi) project, stated: "Developing our own clinical-grade iPSCs using a proprietary, virus-free protocol is a monumental step forward for the UAE and the global medical community. This accomplishment not only reinforces Abu Dhabi's position as a hub for cutting-edge medical research but also opens the door to transformative therapies that can address some of the most complex diseases. The success of this project reflects our commitment to delivering safe, innovative, and personalized solutions to patients worldwide. Our team of scientists will be publishing our scientific findings in leading medical journals."

Unlike traditional methods that use viruses to reprogramme cells, ADSCC's approach avoids genetic modification. This significantly reduces risks like cell transformation or tumor formation. Their process adheres to strict clinical standards, ensuring iPSCs are suitable for therapeutic use. This innovation highlights ADSCC's dedication to developing safe and effective regenerative therapies.

Professor Angelo Vescovi from Link Campus University of Rome and an advisor at ADSCC explained: "Induced pluripotent stem cells are a cornerstone of personalised medicine. By creating iPSCs from a patient’s own cells, we can generate therapeutic cells tailored to their needs. For example, iPSCs can be differentiated into neural (brain) stem cells for patients with neurodegenerative conditions that could be injected back through intracerebral transplantation in the brain and spinal cord or into pancreatic cells for diabetes. This protocol not only achieves these outcomes but does so with improved safety and reliability, making it a significant advancement toward clinical applications."

Advancing Regenerative Medicine Locally

This development enhances ADSCC's ability to advance regenerative medicine locally by establishing an exclusive protocol for iPSC development. Producing clinical-grade iPSCs within Abu Dhabi ensures better control over quality and availability of these therapies while reducing reliance on external sources.

The achievement aligns with the UAE's vision as a leader in healthcare innovation. With state-of-the-art Good Manufacturing Practice facilities and skilled researchers, ADSCC is poised to translate this breakthrough into life-changing treatments.

Professor Yendry Ventura remarked: "This accomplishment is not just about scientific excellence; it’s about making a difference for patients. The capacity to produce iPSCs locally means we can offer hope to individuals suffering from debilitating diseases. The potential applications are vast, from treating neurological conditions to developing new therapies for chronic illnesses, which will be offered at our hospital in Abu Dhabi."

ADSCC's pioneering work with iPSCs underscores its commitment to advancing stem cell research and personalised medicine. By establishing a routine process for developing clinical-grade iPSCs, they have laid the foundation for future breakthroughs that could transform healthcare globally and bring hope to many patients.

With inputs from WAM